Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 67 for genomics

Edit search filters
  1. A Study to Evaluate Myeloma-Developing Regimens Using Genomics (MyDRUG)

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. A Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome

    Rochester, MN

  3. A Network Genomic Risk Assessment of the Electronic Medical Records and Genomics

    Rochester, MN

  4. Mayo Clinic Health TAPESTRY: Use of Genomic Sequencing in Clinical Practice

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. A Study to Evaluate Food on Gastrointestinal Toxicity and The Effect of Selumetinib in Adolescents with Neurofibromatosis Type 1

    Rochester, MN

  6. A Phase I study of Epalrestat Therapy in a Single Patient with Phosphomannomutase Deficiency (PMM2-CDG)

  7. Combination of Serabelisib and Insulin Suppressing Diet in Subjects With Advanced Solid Tumors with PIK3CA Mutations

    Rochester, MN

  8. A Study of the Response of Feelings, Plans, and Behaviors of People after Learning Outcomes of Genetic Research

    Rochester, MN

  9. A Study to Assess the MEK Inhibitor Mirdametinib (PD-0325901) in Patients with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

    Scottsdale/Phoenix, AZ, Rochester, MN

  10. Myocardial Infarction Genes (MI-GENES) Study

    Rochester, MN

.

Mayo Clinic Footer